Standout Papers

Risks of cancer in BRCA1-mutation carriers 1994 2026 2004 2015 1.4k
  1. Risks of cancer in BRCA1-mutation carriers (1994)
    Daniel Ford The Lancet

Immediate Impact

41 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

From discoveries in ageing research to therapeutics for healthy ageing
2019 StandoutNature
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
2019 Standout
3 intermediate papers

Works of Daniel Ford being referenced

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
2017
The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Daniel Ford 397 438 146 1164 611 39 2.1k
Kirsten Vang Nielsen 218 835 184 322 805 62 1.9k
B A Ponder 159 734 72 1298 1050 39 2.7k
Rosa Ana Risques 179 537 23 336 954 48 2.1k
Irmgard Irminger‐Finger 102 451 45 440 1261 54 1.8k
Zsofia Kote‐Jarai 1264 648 60 1075 1399 91 2.9k
Hanny Odijk 90 440 81 356 2286 26 2.7k
Christopher C. Oakes 157 243 63 329 1696 67 2.5k
Peter Broderick 463 539 17 801 1760 50 2.9k
Erika M. Kwon 794 265 40 519 718 48 1.9k
Lee Anderson 330 825 51 1633 1536 32 3.1k

All Works

Loading papers...

Rankless by CCL
2026